Bio€quity Europe 2026

We’re pleased to be attending @Bio€quity Europe 2026 this week!

Our CEO, Jan Thirkettle, will be presenting on Tuesday at 15:15 CEST, sharing latest progress on our FAN1 programme for Huntington’s disease and plans for taking this into the clinic.

Bio€quity continues to be an important forum for bringing together science, strategy and investment across the biotech ecosystem – we’re looking forward to some great conversations ahead.

#Bioequity #Biotech #Investment #LifeSciences #Innovation #Healthcare

Our programmes

Huntington's Disease

Discover more

ALS and Alzheimer's

Discover more

Our news

February 2026

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board

October 2025

Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

February 2025

Harness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference

View all